Find expertise

The Laboratory of Cell Death Research & Therapy researches Defective regulation of cell death, especially in the form of apoptosis, contributes to the development of crucial pathologies including cancer and plays a major role in chemoresistance. Mechanisms regulating cancer cell death also affect the emission of ‘danger signals’ from the stressed/dying cells, which critically define their ‘immunogenic character’ and impact the initiation ...

The focus of the Laboratory for Molecular and Cellular Therapy (LMCT) is directed towards the application of basic immunological knowledge and molecular biotechnology for the understanding, diagnosis and treatment of human diseases, including cancer, infectious disease and brain disease.

Convincing evidence continues to emerge from clinical trials that gene therapy is yielding therapeutic effects in patients suffering from a wide range of diseases. Moreover. the use of adult stem cells and the reprogramming of cells towards pluripotency are being heralded as some of the most promising developments in regenerative medicine at the forefront of medical innovation. This mirrors worldwide efforts in some of the leading research ...

The laboratory for Neurobiology and Gene Therapy is committed to gain insight in the underlying pathology of Parkinson's Disease (PD) and more recently Multiple System Atrophy (MSA), on both the molecular and cellular level. We are specifically focussing on the proteins α-synuclein and LRRK2, two key players in sporadic and familial PD.  The underlying idea is that better disease models and insights in the molecular pathogenesis are required ...

The Laboratory for Cell Stress & Immunity (CSI) focusses on following research themes: cancer immunology & immunotherapy (e.g. DC vaccines, immune-checkpoint blockers, chemo-immunotherapy), immunology of cancer cell death (e.g. programmed cell death like apoptosis, necrosis & necroptosis; stress responses, inflammation, immunity), stress or therapy-elicited immune-signalling pathways (e.g. type I interferons, NFkB signalling, ...